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Sarcoidosis is a multisystem granulomatous inﬂammatory disease of unknown etiology. There is evi-
dence that Tumor Necrosis Factor alpha (TNF-a) antagonists are useful in the treatment of advanced or
refractory disease. However, sarcoidosis-like reaction has been reported with TNF-a blockade in other
inﬂammatory conditions. Here we report a case of sarcoid-like reaction in a patient with psoriatic
arthritis shortly after initiation of adalimumab therapy. Stopping adalimumab and systemic anti-
inﬂammatory therapy with corticosteroids resulted in resolution of pulmonary symptoms and chest
radiographic ﬁndings. Though TNF-a plays a critical role in pathogenesis of sarcoidosis, the development
of sarcoid reaction with TNF-a blockade is paradoxical and the mechanism of this response remains
unknown. TNF-a induced sarcoid-reaction could involve multiple organs. Its development with one
agent does not preclude therapy with other TNF-a blockers.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Tumor Necrosis Factor (TNF) is a pro-inﬂammatory cytokine
produced by activated macrophages, CD 4þ lymphocytes, NK cells
and other cells. Hence, agents blocking TNF-a are widely used for
the treatment of various immune mediated inﬂammatory condi-
tions such as rheumatoid arthritis [1], psoriatic arthritis [2] and
ankylosing spondylitis. TNF- a blockers have also proven effective
in treatment of granulomatous inﬂammatory diseases such as
sarcoidosis [3e5], Crohn’s disease and granulomatosis with poly-
angiitis (Wegener’s) [6], conditions where TNF-a is critical in
pathogenesis. Most commonly used TNF-a antagonists include
etanercept which is a fusion protein that binds TNF-a bymimicking
the soluble TNF receptor, inﬂiximab and adalimumab, which are
monoclonal antibodies against TNF-a. These agents have demon-
strated variable therapeutic efﬁcacy in sarcoidosis and other in-
ﬂammatory conditions, presumably owing to different binding
characteristics to TNF-a. In a recent study, adalimumab compared
to etanercept or inﬂiximab was more effective in the treatment ofSE, Minneapolis, MN 55455,
).
r Ltd. Open access under CC BY-NC-NDpsoriasis [7] thus making it an important option in therapy. How-
ever, like other TNF antagonists, adverse effects have been observed
with adalimumab.
Although TNF-a antagonists are effective in treatment of
sarcoidosis, a paradoxical sarcoid-like reaction [8] has been seen in
approximately 1/2800 patients treated for inﬂammatory arthrop-
athies [9]. A survey of the literature revealed 52 cases [10e21]
where the use of TNF-a antagonists has led to the development
of a sarcoid-like reaction. Among those cases 33 were treated with
etanercept, 12 with Inﬂiximab and 7 with adalimumab. A majority
of the adalimumab cases had a diagnosis of rheumatoid arthritis
with only one case of sarcoid-like reaction in a patient with pso-
riasis. Here, we describe another case of psoriatic arthritis being
treated with adalimumab who developed a sarcoid-like reaction
that showed complete resolution with discontinuation of adali-
mumab in combination with anti-inﬂammatory therapy.
2. Case report
31-year-old white female presented to the pulmonary clinic for
evaluation of fevers. She had been diagnosed with psoriatic
arthritis 18 months prior. Her initial treatment was with inﬂiximab
monotherapy. Subsequently, cyclosporinewas added due to limited
beneﬁt from inﬂiximab. Due to lack of response in joint symptoms,
inﬂiximab was switched to adalimumab. Two months later, she
started having fevers for which the adalimumabwas held and fever
workup performed. However, due to recurrence of joint pain, one license.
Fig. 2. Transbronchial biopsies performed at presentation reveal non-caseating, well-
formed granulomas involving lung tissue. No fungal or acid-fast organisms were
identiﬁed (with appropriate controls).
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evaluation in the pulmonary clinic. For the persistent fevers and
shortness of breath a chest radiograph was performed which
showed inﬁltrates prompting further evaluationwith chest CT Scan
which is shown in Fig. 1 (panel A and B). As there was a mediastinal
mass (concerning for lymphoma), a PET scan was also done which
demonstrated increased uptake in the lymph nodes, but the mass
behind the sternum did not demonstrate high metabolic activity,
suggesting it was thymic hyperplasia (FDG PET images not shown).
Transbronchial biopsies were performed which showed non-
necrotizing granulomas (Fig. 2). Histopathological stains were
negative for malignancy and no acid-fast bacilli or fungal elements
were identiﬁed. Antigens for Histoplasma and Legionella
(serogroup 1) in urine were also negative. Fungal antibodies were
also negative. No bacterial organisms were identiﬁed (including
Mycobacterium tuberculosis) on culture of the bronchoalveolar
lavage ﬂuid. Adalimumabwas held and systemic anti-inﬂammatory
treatment with prednisone was initiated which resulted in
improvement with the imaging abnormalities, fevers and the pul-
monary symptoms. Chest CT scan obtained at seven months had
minimal residual inﬁltrates, which completely resolved on the CT
scan done at 23 months (Fig. 1 panel C and D).3. Discussion
TNF-a antagonists have shown potential for remedying symp-
toms of immune-mediated inﬂammatory arthropathies including
psoriatic arthritis. However, a number of recent reports have shown
an association of sarcoid-like reaction in psoriatic arthritis patients
getting anti TNF-a therapy, resulting in the formation of non-
necrotizing granulomas in multiple organs. Here we describe a
patient with a diagnosis of psoriatic arthritis who developed
sarcoid-like reaction in the lung while being treated with adali-
mumab. The patient presented with symptoms after initiatingFig. 1. Chest CT scan images lung windows (panel A and C) and mediastinal windows (p
perilymphatic distributed micronodular opacities (Galaxy Sign- Panel A) and bilateral hila
months showed complete resolution of the parenchymal micronodules with signiﬁcant imtreatment with adalimumab, diagnostic evaluation for the pre-
senting symptoms showed bilateral hilar and subcarinal lymph-
adenopathy with parenchymal inﬁltrates and biopsy of the lesions
revealed non-necrotizing granulomas similar to those seen in
sarcoidosis. Adalimumab was withdrawn and prednisone was
initiated which gradually led to the resolution of symptoms and
improvement in imaging abnormalities. Long term follow up
revealed no imaging abnormality at approximately 2 years after the
diagnosis of sarcoid reaction from treatment with adalimumab.
The molecular mechanism underlying the paradoxical
sarcoid-like reaction upon treatment with TNF- a antagonists is
presently unknown despite improved understanding of the earlyanel B and D). At presentation the lung windows demonstrated bilateral asymmetric
r and subcarinal lymphadenopathy (panel B). Subsequent chest CT scan images at 23
provement of the lymphadenopathy except mildly enlarged right hilar lymph node.
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trigger, immune response is initiated by mobilization and activa-
tion of CD4þ T helper cells resulting in secretion of cytokines such
as IFN-g and Interleukin-2. These cytokines act as chemo-
attractants and recruit fresh macrophages, neutrophils and other
lymphocytes. Subsequent activation of macrophages release TNF-a
that mediates formation of granulomas by activating multiple
signaling pathways resulting in increased collagen synthesis,
angiogenesis and activation of NFkB signaling pathway [23]. Thus,
inhibition of TNF-a response by its antagonists should result in less
granuloma formation. However, it is postulated that the cytokine
imbalance caused by neutralization of peripheral TNF-a activate
speciﬁc auto-reactive T-cells which result in sarcoid-like reaction in
patients treated with TNF-a antagonists [24].
In addition to sarcoidosis, this paradoxical inﬂammatory reac-
tion with TNF blockade has been shown in other autoimmune
disease as well. There have been case reports of drug-induced lupus
[25,26], psoriasis [27] and vasculitis [28,29] caused by anti-TNF
therapy. Interstitial lung disease other than sarcoidosis has also
been reported with TNF blockadeutz. When presenting with
sarcoid-like reactions, all three agents discussed have been re-
ported to cause both pulmonary and extra pulmonary disease.
However, the three commonly used TNF blockers are not equiva-
lent. It is interesting to note that a large majority of the case reports
of anti-TNF-a therapy induced sarcoid-like reaction involve eta-
nercept, which is not effective in the treatment of sarcoidosis and
may even exacerbate the disease [30]. These variations could be
attributed to different modes of action of TNF-a antagonists [6,31].
While inﬂiximab and adalimumab bind both soluble monomeric
and trimeric TNF-a and trans-membrane TNF-a, etanercept binds
only to soluble trimeric TNF-a with reduced afﬁnity to the trans-
membrane portion of TNF. Also, the complex interaction between
these agents and other occupational/environmental exposures [32],
genetic factors [33] and other concomitant use of immunosup-
pressive medications are potentially important though poorly un-
derstood. Paradoxical inﬂammatory response with one TNF-a does
not preclude use of other TNF blocking agents. However new
therapeutic options including ustekinumab, abatacept, IL-17 in-
hibitors, apremilast, JAK inhibitors, and possibly IL-6 inhibitors [34]
might be useful for patients who develop sarcoid reaction to TNF-a
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